

Principles of Radiopharmacology

Volume II

Editor

Lelio G. Colombetti, Sc.D.



Principles of Radiopharmacology

Volume II

Editor

Lelio G. Colombetti, Sc.D.

Professor of Pharmacology
Loyola University Stritch School of Medicine
Maywood, Illinois
Nuclear Medicine Division Staff
Michael Reese Hospital and Medical Center
Chicago, Illinois



CRC PRESS, INC.
Boca Raton, Florida 33431

Library of Congress Cataloging in Publication Data

Main entry under title:

Principles of radiopharmacology

Bibliography: p.

Includes index.

1. Radioisotopes in pharmacology. I. Colombetti, Lelio G. II. Title: Radiopharmacology. [DNLM:

1. Nuclear medicine. 2. Radioisotopes—Diagnostic use. 3. Radioisotopes—Therapeutic use. WN440 P957]

RM858.P74 615'.19 78-27853

ISBN 0-8493-5465- (v. 1)

This book represents information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Every reasonable effort has been made to give reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

All rights reserved. This book, or any parts thereof, may not be reproduced in any form without written consent from the publisher.

© 1979 by CRC Press, Inc.

International Standard Book Number 0-8493-5465-X (Volume I)

International Standard Book Number 0-8493-5466-8 (Volume II)

International Standard Book Number 0-8493-5467-6 (Volume III)

Library of Congress Card Number 78-27853

Printed in the United States

PREFACE

In less than two decades radiotracers and their applications to medicine have emerged from a position as a minor branch of chemistry to that of an independent discipline. The best proof of this thesis are the many teaching programs in radiopharmacy which demonstrate practical utility of radiotracers in medicine. Radiotracers have been applied to solve a wide variety of diagnostic problems. For example, the behavior of specific radiotracers changes from normal in disease states facilitating diagnosis; when localization or metabolism of the radiotracer occurs in specific organs in a predictable manner; when the uptake and concentration data yield information about the state of metabolism in an organ or part of an organ, etc.

There is an area in the medical application of radiotracers that has been neglected up to now. This area involves the study of the mechanisms by which the radiotracers are transported in a biological system, the mechanisms of localization of radiotracers in the cell, and the metabolic pathways of radiotracers. These aspects of radiotracer biochemistry are especially important if we want to know how to create more specifically labeled compounds. The significance of these *in vivo* radiotracer properties created the necessity for a course in which these aspects were taught. And from this course, which we called from the very beginning a "course in Radiopharmacology", because radiotracers act in a biological system in a similar manner to drugs — even if a pharmacological effect is not noticeable or desired — a symposium was organized and held in Innsbruck, Austria in May 1978. The widespread interest in the subject is evident from the list of sponsors: The Loyola University Stritch School of Medicine, the Society of Nuclear Medicine (U.S.A.), and its counterpart in Europe, the American College of Nuclear Physicians, local European societies of nuclear medicine, etc. Also, the large number of participants — 388 scientists representing 37 countries from all continents — in a symposium of such a specific concern is a recognition of the significance of this subject.

This book is an outgrowth of the symposium and it is intended to be used by scientists and clinical personnel involved in the further evolution of radiotracer research. Hopefully, it will serve as a reference book for all scientists working in the development of new radiotracers. It is also intended to serve as a textbook in the teaching of radiopharmacology to science and medical students. This publication is the first to present a comprehensive and integrated summary of the perspective of all the disciplines of the basic sciences that are fundamental to the understanding of the biological behavior of radiotracers.

The book is divided into five major areas:

1. Basic radiopharmacology techniques
2. Radiotracer design
3. Basic radiotracer and receptor properties
4. Biological transport of radiotracers
5. Mechanisms of localization of radiotracers

The subjects comprising these five general areas are basic to the aim of the book: to help prepare the scientists that will develop the radiotracers of the future.

The editor acknowledges most gratefully the contributions of the authors, extending to all of them our deep appreciation for their patience for the delays occasioned by the necessity of reviewing several times each manuscript. Every attempt has been made to make the texts as complete as possible, incorporating new and bold ideas which we hope will help the development of new radiotracers.

Several scientists made important contributions to this publication by contributing

to the success of the symposium from which this book evolved. I am referring to the members of all the committees involved in the preparation of the symposium and especially to Dr. W. Earl Barnes who spent countless hours in helping to organize the symposium, to Dr. Richard Reba, chairman of the scientific committee, to Dr. Howard Glenn who also helped in the organization of the symposium; the inspiration and support received from Dr. Alexander Karczmar, Chairman of the Department of Pharmacology at Loyola University School of Medicine; to Dr. Steven Pinsky, Director of the Division of Nuclear Medicine at Michael Reese Hospital and Drs. John J. Coupal, Garimella Rayudu, and so many others, whose names are not mentioned here but who are well remembered. To all of them my sincere thanks and appreciation.

Lastly, I would like to thank the large group of scientists from all over the world who joined us in Innsbruck and who encouraged and inspired us during this time. I hope that all of them will be at hand when the next event comes to be.

Lelio G. Colombetti

FOREWORD

There was only one international symposium devoted to radiopharmaceutical drug research and development in the decade from 1965 through 1974. However, during and since this interval, there has been a veritable explosion of presented and published material concerning the design, preparation, and verification of new labeled drugs. Improvements in instrumentation, data analysis, and increased clinical awareness of the importance of biochemical processes in the diagnosis and clinical management of disease have served to stimulate the developing field of radiopharmacology. This provocation resulted in the First International Symposium on Radiopharmacology. The general goals of the meeting are notable: (1) to make diagnoses more specific; (2) to improve the quantification of serial physiological and biochemical changes *in vivo*; (3) to improve radiolabeled drugs in order to reduce absorbed radiation dose to patients; and (4) to compile in one publication the fundamental principles of an emerging discipline, radiopharmacology.

Although in the past, the search for special labeled drugs has been based on the concept of the "magic bullet", the facts are that many of the labeled drugs currently used were uncovered fortuitously. Most past discoveries were the result of empirical methods, or chance alone. As emphasized by Dr. Henry Wagner, an understanding of regional function, i.e., organ function, cellular function, membrane function, and intracellular function will be more useful to the development of new labeled drugs than the idea of a magic bullet or any special attraction of an abnormal focus. Concepts of disease more than 100 years old, such as Virchow's idea that disease was due to abnormal cellular function and Bernard's idea that disease was due to some derangement in internal milieu (a physiochemical or internal physiology change), long believed to be true, can now be studied, refined, and exploited fully in clinical investigations and patient care.

Since one of the greatest frustrations to the advancement of nuclear medicine is the absence of convenient gamma-emitting radionuclides of carbon, hydrogen, oxygen, and nitrogen, an immense effort has been expended toward identifying biologically important molecules that can be linked to a radiolabel in a biologically inert portion of the molecule so that the biologic activity of the parent molecule remains unperturbed.

In order to use a rational approach to new drug development, it is apparent that one must understand the biological disposition, the biochemistry, and the immunology of proposed compounds. Likewise, drug metabolism and knowledge of the mechanisms of localization, including the pharmacokinetics of the compound of interest, will all lead to an understanding of the structure-activity and drug-receptor relationships so that molecular manipulation will lead to specific analogs or derivatives. An appreciation of the usefulness of these tenets of pharmacology to the development of more specific radiotracers were the specific goals of this symposium. As emphasized by many, it is now clear that progress in the development of new radiotracers will require that radiopharmacy evolve to become radiopharmacology.

We are now beginning to "see" cellular structure and function by noninvasive nuclear recording techniques. Internal physiology and internal cellular biochemistry can be followed by measurement of changes in time and distribution. An understanding of radiopharmacology will give critical importance to further advances in the development of new radiotracers and, therefore, nuclear medicine itself.

The First International Symposium on Radiopharmacology brought together diverse individuals from different countries, having different languages, different cultures, and, therefore, different problems and working to solve different medical illnesses. The common bond was science and the application of the scientific method to uncover

and understand the basic means which could be used to solve different problems. This work is being integrated into what is becoming a new scientific discipline, one directed toward the investigation of *kinetics* and *actions* of drugs, and based primarily on biokinetics. **PRINCIPLES OF RADIOPHARMACOLOGY** fills a timely need for a comprehensive, up-to-date text in this new discipline, one that will be used as a text by students and a reference by nuclear medicine physician specialists, residents, radiopharmacists, and scientists working in the preparation and uses of radiotracers in biology and medicine. The editor, Dr. Lelio G. Colombetti, has devoted a considerable effort during the last seven years to the development of university program in radiopharmacology, and he has been able to bring together a distinguished group of scientists for the preparation of the book. It is important to recognize radiopharmacology as a necessary tool for the development of the new radiotracers that will satisfy medical needs. If we are to advance from serendipitous and random discovery of new radiotracers to an approach that includes a rational basis for progression, then the principles and techniques discussed in the book must be learned and refined.

Richard C. Reba, M.D.

THE EDITOR

Lelio G. Colombetti, Sc.D., is Professor of Pharmacology at Loyola University Stritch School of Medicine in Maywood, Ill. and a member of the Nuclear Medicine Division Staff at Michael Reese Hospital and Medical Center in Chicago, Ill.

Dr. Colombetti graduated from the Litoral University in his native Argentina with a Doctor in Sciences degree (*summa cum laude*), and obtained two fellowships for postgraduate studies from the Georgetown University in Washington, D.C., and from the M. I. T. in Cambridge, Mass. He has published more than 150 scientific papers and is the author of several book chapters. He has presented over 300 lectures both at meetings held in the U.S. and abroad. Recently he organized the First International Symposium on Radiopharmacology, which took place in Innsbruck, Austria in May 1978 with an outstanding success, and is presently organizing a second international symposium on the same subject.

Dr. Colombetti is a member of various scientific societies, including the Society of Nuclear Medicine (U.S.) and the Gesellschaft für Nuklearmedizin (Europe), and is an honorary member of the Mexican Society of Nuclear Medicine. He is also a member of the Society of Experimental Medicine and Biology, the Coblentz Society, and the Sigma Xi. He is a member of the Editorial board of *Nuklearmedizin* journal.

A SHORT HISTORY MADE SHORTER

... and great changes, indeed, are taking place for us, because the field of radiotracer application in medicine is taking a sharp turn in its march toward a greater future. Today we believe that static imaging will, in great part, be replaced by dynamic studies in which not only the anatomical integrity of an organ can be studied, but also the physiological response of the cells. And to do this job we need, in many cases, to develop the appropriate radiotracer.

More than three decades ago, Hamilton stated that "the discovery of artificial radioactivity and the development of the cyclotron, have given the biologist the most useful tools since the discovery of the microscope". Soon after von Hevesy introduced the radiotracer concept into chemistry and later into biology, it was proved that the amount of radiotracer needed to study a process was so small that it could not disturb the system under investigation. This peculiar characteristic allows the use of radiotracers to study the function of cells.

After the Joliot's invented the artificial production of radionuclides in 1934 and Lawrence invented the cyclotron, a large number of artificially produced radiotracers became available and their applications in the biological and medical sciences increased manifold in a short period of time.

It is interesting to note that radiotracers were first used for therapeutic purposes. It took more than fifteen years before a tracer was used for the first time in diagnosis, and, incidentally, the first uses were in dynamic studies.

A written history of the uses of radiotracers in their most important application, medicine, could start with the work done by Wickman and Desgrais in Paris in 1911. These investigators by subcutaneous administration of radium attempted to cure lesions of lupus. Later, radium was used by many investigators for the treatment of a variety of diseases, with negative results in most cases. Other radionuclides — when they became available — were also used, such as radiobismuth which was used by Lomholt in an attempt to cure syphilis.

To the best of our knowledge, the first human application of a radiotracer for diagnostic purposes was the use in the mid-twenties of ^{228}Ra by Yens, Blumgart and Weiss to study the blood circulation time in the human. Several years later von Hevesy used ^3H to determine the water content of the human body.

Soon after the Joliot's discovered the production of radionuclides by artificial means in the early forties, and Fermi produced the first man-made radioiodine by using a radium-beryllium source, other radionuclides were introduced rapidly. ^{131}I was produced by the Berkeley and Massachusetts groups in their cyclotrons as early as 1938. Chiewitz and Hevesy used in 1935 the newly produced ^{32}P to study phosphorous metabolism in the bones. ^{32}P was used later by John Lawrence to treat leukemia. By this time cyclotrons were built in other universities and scientists started using the newly found radionuclides. The discovery of ^{14}C at Oak Ridge in 1946 opened a floodgate of metabolic studies and in just a few years many investigations were performed to study the pathway of naturally occurring biochemicals and drugs. Reactor radionuclides produced by the neutroactivation of stable nuclides became available in the forties. This development led to the production of a number of radionuclides with special value for medical applications.

The discovery of the ^{99}Mo - $^{99\text{m}}\text{Tc}$ generator and the work done by Harper and associates introduced a new concept in the preparation of radiotracers. Today, most radiotracers used in human studies are based on molecules labeled with $^{99\text{m}}\text{Tc}$. Very recently other radionuclides such as ^{67}Ga and ^{201}Tl have been introduced and proved to be very valuable as diagnostic tools. These radionuclides have gained in popularity during the last few years, but we strongly believe that they will be replaced in the near future by

labeled molecules with specific localizations.

Until recently, most of the radiotracers developed for medical applications were based on labeling known drugs or on empirical approaches. Soon, the need for radiotracers outstripped the number of available agents. In order to develop new radiotracers, scientists working in this field applied known concepts of biochemistry and physiology. But their efforts were not sufficient to satisfy the needs.

More recently different approaches have been suggested, approaches that involve a variety of scientific disciplines, such as biochemistry, biophysics, physiology and pharmacology. The creation of biological models to study the mechanism of transport and localization, and metabolic pathways is helping researchers to solve the problems encountered with the development of radiotracers with specific localization. No need is greater than that of a better understanding of what happens to radiotracers once they are administered and the changes they suffer in a biological system, which, in turn, influence their disposition by the body.

As it was once said, "it is very difficult to make predictions . . . especially about the future . . ." anyhow we dare to predict today that with the passing of time there will be an increasing need for radiotracers suitable for measuring dynamic processes in the assessment of organ function. Also, assessment of organ perfusion and fate of radiometabolites will comprise a large portion of radiotracer use in medicine and biology. So we can say with confidence that a chapter in the history of radiotracers has been closed and that a new chapter is being opened . . . "for all those who dare to work for the future".

CONTRIBUTORS

William H. Beierwaltes, M.D.
Professor of Medicine
Director
Nuclear Medicine Division
University of Michigan
Ann Arbor, Michigan

Madeleine Besnard, M.S.
Radiochemist
Laboratoire de Pharmacodynamie
Universite de Paris Sud
Chatenay Malabry, France

Vaclav Blaha, C.Sc.
Senior Lecturer of Nuclear Medicine
Department of Nuclear Medicine
School of Medicine and Hygiene
Charles University of Prague
Czechoslovakia

Leopoldo L. Camin, M.S.
Technical Director
Radiopharmaceutical Research
Medical Diagnostics Division
New England Nuclear Corporation
North Billerica, Massachusetts

Yves Y. Cohen, Ph.D.
Professor, Head
Department of Pharmacodynamics
Dean of the School of Pharmacy
Universite de Paris Sud
Chatenay Malabry, France

Lelio G. Colombetti, Sc.D.
Professor of Pharmacology
Loyola University Stritch School of
Medicine
Maywood, Illinois
Nuclear Medicine Division Staff
Michael Reese Hospital and Medical
Center
Chicago, Illinois

Raymond E. Counsell, Ph.D.
Professor of Pharmacology and
Medicinal Chemistry
Department of Pharmacology
The University of Michigan
Ann Arbor, Michigan

Elizabeth J. Crawford
Associate Specialist
Department of Biology
University of California, San Diego
La Jolla, California

William C. Eckelman, Ph.D.
Professor of Radiology
Chief
Section of Radiopharmaceutical
Chemistry
George Washington University
Medical Center
Washington, D.C.

Alberto Fini, Ph.D.
Radiochemical Assistant
Nuclear Medicine Service
Ospedale Maggiore Bologna
Italy

Ernest W. Fordham, M.D.
Chairman, Nuclear Medicine
Professor of Nuclear Medicine and
Radiology
Department of Nuclear Medicine
Rush University Medical Center
Chicago, Illinois

Joanna S. Fowler, Ph.D.
Chemist
Chemistry Department
Brookhaven National Laboratory
Upton, New York

Morris E. Friedkin, Ph.D.
Professor of Biology
Department of Biology
University of California, San Diego
La Jolla, California

Brian M. Gallagher, Ph.D.
Pharmacology Group Leader
Department of Research
New England Nuclear Corporation
North Billerica, Massachusetts

Raymond E. Gibson, Ph.D.
Assistant Professor
Section of Radiopharmaceutical
Chemistry
George Washington University
Medical Center
Washington, D.C.

Richard A. Holmes, M.D.
Professor of Medicine and Radiology
University of Missouri
Chief, Nuclear Medicine Service
Harry S. Truman Memorial Veterans
Hospital
Columbia, Missouri

Victor W. Jiang
RIA Development and Research
Kaiser Regional Laboratory
Berkeley, California

William H. Klausmeier, Ph.D.
Diamond Shamrock Corporation
Franklin Park, Illinois

Toru Komai, Ph.D.
Assistant Chief Researcher
Central Research Laboratories
Sankyo Co. Ltd. (Tokyo)
Tokyo, Japan

Richard M. Lambrecht, Ph.D.
Scientist
Chemistry Department
Brookhaven National Laboratory
Upton, New York

Robert R. MacGregor
Chemistry Department
Brookhaven National Laboratory
Upton, New York

J. Krijn Mazaitis
Research Associate
Section of Radiopharmaceutical
Chemistry
George Washington University
Medical Center
Washington, D.C.

Fedor Medzihradsky, Ph.D.
Associate Professor
Departments of Biological Chemistry
and Pharmacology
The University of Michigan Medical
School
Ann Arbor, Michigan

Chang H. Paik, Ph.D.
Assistant Research Professor
Section of Radiopharmaceutical
Chemistry
George Washington University
Medical Center
Washington, D.C.

Garimella V. S. Rayudu, Ph.D.
Senior Scientist and Associate
Professor
Department of Nuclear Medicine
Rush University Medical Center
Chicago, Illinois

Richard C. Reba, M.D.
Professor of Radiology and Medicine
Director
Division of Nuclear Medicine
George Washington University
Hospital
Washington, D.C.

Waclaw J. Rzeszutarski, Ph.D.
Associate Research Professor of
Radiology
Section of Radiopharmaceutical
Chemistry
George Washington University
Medical Center
Washington, D.C.

Eugene L. Saklad, Ph.D.
Assistant to the Technical Director
Radiopharmaceutical Research
Medical Diagnostics Division
New England Nuclear Corporation
North Billerica, Massachusetts

Edward Siegel, Ph.D.
Professor and Director of Radiation
Biology
Department of Radiology and
Radiological Sciences
Vanderbilt University School of
Medicine
Nashville, Tennessee

Elsie P. Siegel, M.S.
Research Associate
Department of Radiology and
Radiological Sciences
Vanderbilt University School of
Medicine
Nashville, Tennessee

Dennis P. Swanson, M.S.
Director
Nuclear Pharmacy
Division of Nuclear Medicine
University of Michigan
Ann Arbor, Michigan

Donald M. Wieland, Ph.D.
Director of Radiopharmalogical
Research and Development
Division of Nuclear Medicine
University of Michigan
Ann Arbor, Michigan

Alfred P. Wolf, Ph.D.
Senior Chemist
Chemistry Department
Brookhaven National Laboratory
Upton, New York

Yukio Yano
Chemist
Radiopharmaceutical Development
Donner Laboratory
University of California
Berkeley, California

A. Michael Zimmer
Section of Nuclear Medicine
University of Illinois Medical Center
Chicago, Illinois

Volume II

PART III: BASIC RADIOTRACER AND RECEPTOR PROPERTIES

Introduction	2
Lelio G. Colombetti	
Molecular Properties of Radiotracer Receptors	5
A. Michael Zimmer	
Radiotracer Localization by Receptor-Ligand Interactions	17
Raymond E. Gibson, William C. Eckelman, W. J. Rzeszutarski, Victor Jiang, J. Krijn Mazaitis, Chang H. Paik, Toru Komai, and Richard C. Reba	
Radiolabeled Enzyme Inhibitors for Imaging	41
William H. Beierwaltes, Donald M. Wieland, and Dennis P. Swanson	
Radiotracer Interactions with Sex Steroid Hormone Receptor Proteins (Receptor Mapping)	59
Raymond E. Counsell and William H. Klausmeier	
Stimulating and Depressing Radiotracer Metabolism	93
Garimella V. S. Rayudu and Ernest W. Fordham	
In Vitro Experiments to Demonstrate Radiotracer Metabolism	107
Edward Siegel and Elsie P. Siegel	
In Vivo Measurement of Transport and Metabolic Processes Using Radiotracers ...	135
Brian M. Gallagher, Joanna S. Fowler, Robert R. MacGregor, Richard M. Lambrecht, Alfred P. Wolf, Elizabeth J. Crawford, and Morris E. Friedkin	
Fate of Radiometabolites	155
Yves Y. Cohen and Madeleine Besnard	
Adverse Reactions to Radiotracers	165
Vaclav Blaha and Lelio G. Colombetti	
In Vitro Stability of Radiotracers	179
Leopoldo L. Camin and Eugene L. Saklad	

PART IV: BIOLOGICAL TRANSPORT OF RADIOTRACERS

Introduction	195
Lelio G. Colombetti	
Structure and Function of Cell Membranes, and Cellular Transport of Drugs	197
Fedor Medzihradsky	
Effect of Transport in Distribution of Radioions and Radiolabeled Metabolites	225
Yukio Yano	

Effects of Solute Structure in the Transport of Radiotracers	241
Alberto Fini	
Techniques to Study the Transport of Radiotracers	247
Richard A. Holmes	
Index	261

Part III

Basic Radiotracer and Receptor Properties

INTRODUCTION

Lelio G. Colombetti

As it has been repeatedly said, radiotracers act in a biological system in a manner similar to drugs. They will be transported from the site of administration into the site of action by mechanisms of fixation or concentration. To act in this way, the radiotracer should have definite properties that will allow the material to behave in that particular manner.

The radiotracers of great interest are those that are known to concentrate in the target organ or tissue as a result of metabolic activity or binding to specific receptors in the tissue cells. It is evident that the receptor site plays an important part in the localization of radiotracers; therefore, the study of the chemical and/or physical properties of radiotracers should be done having in mind the properties of the possible receptor sites.

The concept of receptors is not a new one. It was experimentally conceived by Ehrlich at the beginning of this century when he proposed that some agents have specific groups that will interact with "side chains" in the cells. Despite the fact that very little is known about the molecular structure of receptors, the evidence of their existence is overwhelming, and the receptor concepts and actions are well established in pharmacology.

The site where the radiotracer is bound, so that it can be transported through the biological system, is the first receptor, made mostly by beta-globulins, albumin, and other blood serum components. Usually this binding is weak, and the material, once it is transported to the specific tissue or organ, will be "transferred" to the receptor inside the cells and into the membranes of the cells of the target.

Knowing the chemical properties of the receptor sites, as well as their physical characteristics, such as molecular volume and spatial distribution, is very important in the development of new radiotracers, because specific chemical groups could be coupled to the main molecule of the tracer, creating in this way an appropriate binding end.

Studies of the receptor-ligand interactions can be done in many different ways, but, as always in a well-designed program, the theoretical development is very important before the task of creating new binding molecules is started. Biological tests can be done in two different ways: (1) studying the *in vivo* kinetics and localization of the radiotracer in living organisms or (2) by doing *in vitro* studies using cell cultures.

It is very important to know the metabolic pathways of the radioactive fraction of the molecule, because it can localize in a different tissue or organ, developing an erroneous image of its true action. The fate of the radiotracer should, therefore, be known if possible, and it will depend mainly on its chemical properties because from these properties will depend its metabolic pathway.

This section of the book deals with some of the most important properties of radiotracer and receptor sites in the cells and with the metabolic pathways of radiometabolites.

原书缺页